SLC5A1 and diabetes mellitus: In conclusion, this study showed that EMPA, a highly selective SGLT2 inhibitor, and SOTA, a dual SGLT1/2 inhibitor, provide similar cardioprotective effects in a zebrafish model of DM-HFrEF.